✨ Your Portfolio is fetched and updated from zerodha.

Epigral Ltd.

EPIGRAL

Market Cap
₹7,833 Cr.
P/E
22.50

Epigral Ltd.

About
Epigral Limited (Formerly known as Meghmani Finechem Limited) is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives. The company is also engaged in trading of Agroche… Read more
Epigral Limited (Formerly known as Meghmani Finechem Limited) is primarily engaged in manufact… Read more
Low
940
52W Range
High
2408
  • Epigral
  • DCM Shriram
  • Guj. Alkalies & Chem

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Company Timeline

Subscribe now for more updates
Custom financial statementNew
Edit rows
Forensics

11 Yes

Positive for this company

1 Neutral

Neutral for this company

4 No

Negative for this company

1 No Data

Insufficient data to analyse

Market Share
0 %
(as of Mar 22)
Source/Historic
Chlor-Alkalis - Market Share
Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Asset Break-Up

Operational Metrics

    locked
    Select a Metric
    • Manufacturing Capacity - Caustic Soda (MTPA)
      Source
    • Realization / Tonne - Caustic Soda (Rs/MT)
      Source
    • Manufacturing Capacity - Caustic Potash (MTPA)
      Source
    • Capacity Utilization - Chemicals (%)
      Source
    • Capacity Utilization - Chlor-Alkali (%)
      Source
    • Manufacturing Capacity - Chloromethanes (MTPA)
      Source
    • Manufacturing Capacity - Hydrogen Peroxide (MTPA)
      Source
    • Manufacturing Capacity - CPVC Resin (MTPA)
      Source
    Peer Comparison
    FAQs on Epigral Ltd. Business

    Epigral Limited, formerly known as Meghmani Finechem Limited, is a leading ISO-certified company manufacturing and selling Chlor Alkali & its Derivatives with backward and forward integration facilities.

    Epigral major competitors are DCM Shriram, Guj. Alkalies & Chem, Chemfab Alkalis, TGV SRACC, TN Petro Products, Primo Chemicals, Lords Chloro Alkali.
    Market Cap of Epigral is ₹7,726 Crs.
    While the median market cap of its peers are ₹991 Crs.

    Epigral seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    View FAQ's On Shareprice
    Company Filing
    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call SummaryCon Call Summary Mar Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Discussions & Analysis
    Epigral Ltd.
    From Commodity to Specialty Chemicals - Meghmani Finechem - Logical Investor
    Corporate Governance Red Flags At Meghmani - Logical Investor
    Value Chain - Meghmani Finechem - Dr Prashanth Mishra
    Epigral Ltd: How this chemical company is replacing Chinese Imports - Green Portfolio
    Ideas Dashboard
    Timeline
    Watchlist
    Portfolio
    Alerts
    Research
    Stock Screener
    Market
    Raw Material